David Paul, Managing Director of VectorVest in the UK joined us to talk through stock picking fundamentals, technical analysis and more. Watch the full video here.
Totally agree, for Covid alone it will be an all rounder. capabilities of a PCR, Lateral Flow, Antigen test in one.
Scientists say they have detected irregularities in the blood of long Covid patients that could one day pave the way for a test for the condition.
Imperial College London researchers found a pattern of rogue antibodies in the blood of a small number of people with long Covid.
They hope it could lead to a simple blood test within six to 18 months.
I think it will be quicker than that :-) Design Aptamers for the autoantibodies and boom.
The answer to that is no, no one can except Mr Brown himself. We can all guess, have differing opinions, but for facts we only really have RNS’s and annual reports.
The biggest clue as to what may happen, in my opinion, is something to do with 10 million additional shares (resulting in 20% of the company) earmarked for what must be the remuneration policy because the company has a surplus of cash.
‘The Remuneration Committee provides a formal and transparent review of the remuneration of the Executive Directors and senior employees and makes recommendations to the Board on individual remuneration packages. This includes the award of non-contractual performance related bonuses and share options. Remuneration packages are designed to reward, motivate, retain and recruit individuals. Bonuses are only paid in recognition of performance. The committee comprised Jonathan Freeman (Chairman) and Trevor Brown (CEO). No Director took part in discussions concerning the determination of their own remuneration.’
I am edging towards a combination of both a share bonus and options. Options need cash. Let’s face it, I would sell all my shares if I knew I could purchase twice as many via an options package. Remember, the directors wage bill is very low. £70k a year so expect them to churn.
Sadly yes, here is a link..
There are, on average, about 38 amputations a day due to sepsis and about 1% of sepsis survivors undergo one or more surgical amputations of a limb or digit as a result of sepsis. This could be one limb on a patient or multiple fingers/toes and limbs.
Morning Kainos, Starknight appears to be having a break but for what it is worth I’ll give you my thoughts.
The device mooted should be, there or thereabouts as quick as the Covid test (under 2 mins) as accurate as the Covid test (better than PCR as per the recent RNS whilst also capable of seeing the onset of the condition - below just 100 virions in a sample- previous RNS) with platform tech (detect multiple targets) enabling the device to label and identify the exact type of sepsis (50 most common mentioned as an example) offering incredible accuracy (option for quantification of viral load) enabling the end user to immediately choose the correct remedy and I’m guessing dose rather than the current hope and experimentation which will drastically improve outcomes, not only from a live/die situation, but also a quality of life for the patient as the speed and accuracy offered should also prevent other life changing outcomes such as limb removals.
As Sepsis is a common outcome from the Covid infection and most likely many other infections, hospitalised patients could be monitored for Sepsis offering a level of prevention of the onset of sepsis by nipping it in the bud very accurately and very early. However, that all depends on policies of the end user actively seeking it.
What happens when Government Policy relies on the Public?
Findings 'deeply disappointing'
The NAO warned effectiveness of the service was still being undermined by low levels of public compliance, both in terms of coming forward for testing and adhering to isolating.
It also pointed out that just 14% of the 691 million rapid tests sent out to the public had been registered as used.
Self testing continues to fail the NHS test and trace program in many ways with even greater issues than accuracy, drastic changes are required!
A super quick, super accurate, on site test that can be trusted by the public which has been robustly tested by independent 3rd parties in real world settings offering public confidence is desperately required.
Looking good here to meet the above.
A single route to evaluate new diagnostic tests for COVID-19
CONDOR is accelerating how quickly promising COVID-19 diagnostics make it into real-world use. The platform is evaluating new COVID-19 diagnostics in the settings they will be used, such as in GP surgeries, care homes or hospitals, as well as their performance in laboratory settings.
These tests will be used to support diagnosis and management of patients with suspected COVID-19, and collect data to help develop effective diagnostic pathways for subsequent waves of infection in the post-pandemic setting.
“distinguish between intact viral particles and residual RNA fragments. It is known that RNA fragments are present in nasal and pharyngeal epithelial cells and can yield a positive PCR test result for several weeks after peak viral load has passed.“
I think this confirms we are challenging the global gold standard PCR test.
Aptamer Group has just appointed Jordan Clark as its new chief commercial officer to lead the commercial strategy and business development activities and drive the commercialisation of the Optimer technology across diagnostic and therapeutic sectors.
Dr Arron Tolley, chief executive officer of Aptamer Group, said: “Aptamer technology has great potential to offer faster and cheaper diagnostics and improve drug development to improve outcomes for a range of diseases.
Mark Vaux is a Mutual person - Active
(Paraytec 100% owned by Braveheart)
Mark Vaux is a Mutual person - Active
(Kirkstall 80% owned by Braveheart)
Yep, but beyond that, not only capable of identifying Sepsis full stop, but more importantly it will be capable of identifying which type of infection (Carl mentioned 50 most common, they are only limited by Aptamers which take only 2-4 weeks to create) thus removing the guessing game and allowing for a super quick detailed diagnosis and therefore super quick treatment, the key to treating Sepsis. It will be a device that is extremely hard to beat and certainly ground breaking on a global scale.
So once more, your device is excellent at finding those outdoors on a summer day, we can assume most will be enjoying the sunshine (like me after this post!) but the parameters have to shift to catch those indoors, and that is where LFT’s become pointless. The article states ‘false negatives’. Understand how this happens.
Nonsense, LFT’s can only see people on the streets, gardens and parks on a hot summer day. Paraytec’s device can see all the people on the streets, gardens and parks plus those who remain indoors, sitting in cars or at the shops.
Broaden your mind! Paraytec’s device does scale because one device can repeatedly do 1000’s in a day. One device can carry out daily testing for an entire school, as an example.
Rocqeut, I never mentioned false positives. One last time to try and explain, imagine you are in space looking for a specific person. You have a telescope, you can see the country, you can see the city, you can even see a network of streets, but that is your limit. Therefore you cannot find the person, now switch to Ct 35-40 and you can now see individual streets, individual houses and individual people, now you can find that person.